US009511087B2

(12) **United States Patent**
Frieling et al.

(10) **Patent No.: US 9,511,087 B2**
(45) **Date of Patent: Dec. 6, 2016**

(54) **USE OF ANTITHROMBIN IN EXTRACORPOREAL MEMBRANE OXYGENATION**

(71) Applicant: **rEVO Biologics, Inc.**, Framingham, MA (US)

(72) Inventors: **Johan Frieling**, Natick, MA (US); **Simon Lowry**, Hillsdale, NY (US)

(73) Assignee: **rEVO Biologics, Inc.**, Framingham, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/239,943**

(22) PCT Filed: **Aug. 2, 2013**

(86) PCT No.: **PCT/US2013/053365**

§ 371 (c)(1),
(2) Date: **Feb. 20, 2014**

(87) PCT Pub. No.: **WO2014/022748**

PCT Pub. Date: **Feb. 6, 2014**

(65) **Prior Publication Data**

US 2014/0194360 A1 Jul. 10, 2014

Related U.S. Application Data

(60) Provisional application No. 61/679,345, filed on Aug. 3, 2012.

(51) **Int. Cl.**
A61K 31/727 (2006.01)
A61K 38/57 (2006.01)

(52) **U.S. Cl.**
CPC ***A61K 31/727*** (2013.01); ***A61K 38/57*** (2013.01)

(58) **Field of Classification Search**
CPC A61K 31/727
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,517,294	A	5/1985	Bock et al.
4,632,981	A	12/1986	Bock et al.
4,873,316	A	10/1989	Meade et al.
5,366,894	A	11/1994	Clark et al.
5,576,040	A	11/1996	Moller et al.
5,685,847	A	11/1997	Barry
5,801,063	A	9/1998	Grandics et al.
5,827,690	A	10/1998	Meade et al.
5,843,705	A	12/1998	DiTullio et al.
5,849,992	A	12/1998	Meade et al.
6,268,487	B1	7/2001	Kutzko et al.
6,441,145	B1	8/2002	DiTullio et al.
6,528,699	B1	3/2003	Meade et al.
6,727,405	B1	4/2004	Gordon et al.
7,019,193	B2 *	3/2006	Ditullio et al. 800/7
7,045,676	B1	5/2006	Gordon et al.
7,531,632	B2	5/2009	Perreault
7,550,263	B2	6/2009	Meade et al.
7,928,064	B2	4/2011	DiTullio et al.
7,939,317	B1	5/2011	Gordon et al.
8,173,860	B2	5/2012	Meade et al.
8,257,724	B2	9/2012	Cromack et al.
8,524,688	B2	9/2013	Ekman-Ordeberg et al.
8,551,096	B2	10/2013	Perry et al.
2003/0134796	A1	7/2003	Roemisch et al.
2004/0197930	A1	10/2004	Rosenfeld et al.
2005/0271660	A1	12/2005	Wang
2006/0264357	A1	11/2006	Zikria et al.
2006/0292213	A1	12/2006	Gerber et al.
2007/0037192	A1	2/2007	Ziomek et al.
2007/0292407	A1	12/2007	Ivanov
2008/0026371	A1	1/2008	Russell et al.
2008/0118501	A1	5/2008	Schindler et al.
2008/0299594	A1	12/2008	Rosenfeld et al.
2009/0148458	A1	6/2009	Russell et al.
2010/0016173	A1	1/2010	Nagalla et al.
2011/0082083	A1	4/2011	Magneson et al.
2014/0046033	A1	2/2014	Schindler et al.
2014/0194360	A1	7/2014	Frieling et al.
2014/0206617	A1	7/2014	Frieling et al.
2014/0242182	A1	8/2014	Evans et al.
2016/0129115	A1	5/2016	Magneson et al.

FOREIGN PATENT DOCUMENTS

EP	0 475 354	3/1992

OTHER PUBLICATIONS

Soff, Mar. 2012, A New Generation of Oral Direct Anticoagulants, Arterioscler Thromb Vasc Biol, 32: 569-574.*

Niebler et al., 2011, Antithrombin Replacement During Extracorporeal Membrane Oxygenation, Artificial organs, 35(11): 1024-1028.*

Agati et al., 2006, Use of a Novel Anticoagulation Strategy During ECMO in a Pediatric Population: Single-Center Experience, ASAIO Journal, 52: 513-516.*

Agati et al., Use of a novel anticoagulation strategy during ECMO in a pediatric population: single-center experience. ASAIO J. Sep.-Oct. 2006;52(5):513-6.

Buck, Antithrombin Administration during Pediatric Extracorporeal Membrane Oxygenation. Pediatric Pharmacotherapy: A Monthly Newsletter for Health Care Professionals from the University of Virginia Children's Hospital. Feb. 2013; 19(2): 4 pages.

(Continued)

Primary Examiner — Amber D Steele

(74) *Attorney, Agent, or Firm* — Wolf, Greenfield & Sacks, P.C.

(57) **ABSTRACT**

In one aspect, the disclosure provides methods of suppressing blood clotting and/or preventing hemorrhage in a subject having extracorporeal membrane oxygenation comprising administering antithrombin. In some embodiments, the antithrombin used in the methods disclosed herein is ATryn®.

14 Claims, No Drawings